REG - Avacta Group PLC - Avacta to present data at EORTC-NCI-AACR

AvactaAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251013:nRSM0780Da&default-theme=true

RNS Number : 0780D  Avacta Group PLC  13 October 2025

 

 

Avacta to Present First Dual Payload pre|CISION(®) Medicines Data at the 2025
EORTC-NCI-AACR International Conference on Molecular Targets Symposium

 

Groundbreaking oncology development with the first dual payload peptide drug
conjugate platform, establishing Avacta as a leader in combination therapy
innovation

 

 

LONDON and PHILADELPHIA - October 13, 2025 - Avacta Therapeutics (AIM: AVCT,
'Avacta', 'the Company'), a clinical stage biopharmaceutical company
developing pre|CISION(®), a unique oncology delivery platform, today
announces that the Company will present data on its first dual-payload peptide
drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics in Boston on October 25.

The data highlights the Company's proprietary development enabling two
complementary drugs to be delivered via a single pre|CISION(®) medicine,
representing the first dual payload PDC in the field. Data presented will be
in vitro proof of mechanism for this platform innovation.

Drug combinations are commonly used in cancer therapy to improve outcomes and
mitigate against resistance. This novel approach extends the pre|CISION(®)
technology to allow for the selective and controlled release of two
cancer-targeting payloads directly in the tumor, from a single molecule via
fibroblast activation protein (FAP) cleavage.

 

Previously, development of the pre|CISION(®) platform focused on optimizing
the delivery of single payloads to the tumor microenvironment leveraging the
cleavage event by FAP, expressed in more than 90% of solid tumors. The new
dual payload innovation expands the platform's versatility, opening potential
for more complex and effective oncology treatments.

 

Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:

 

"The development of the first dual payload peptide drug conjugate platform
marks a major leap forward in oncology therapy. This significantly extends the
potential of our innovative pre|CISION(®) platform by implementing
combination cancer therapy in a single medicine.

 

"This new IP builds on the success of our FAP-EXd (AVA6103) program, where we
invented a sustained release delivery mechanism with the platform. Our novel
implementation of the platform extends this observation to now release two
drugs from one pre|CISION(®) molecule. The key factor here is our ability to
target the tumor with a cytotoxic drug and attack the known resistance
mechanism all in one cancer medicine. By building on the prior knowledge, we
have now extended the reach to highly-resistant cancers by targeting key
resistance mechanisms.

 

This drug combination approach demonstrates the value we are building in our
proprietary pre|CISION(®) technology by further underlining its flexibility
and unique potential to expand into novel oncology therapeutic approaches.

 

We look forward to presenting the full data at the 2025 EORTC-NCI-AACR
Symposium later this month."

 

Event details are below and are available online on the 2025 EORTC-NCI-AACR
Symposium website.

 

Title: Discovery and characterization of novel pre|CISION(®) technology
compounds delivering complementary dual payloads to the tumor microenvironment
following FAP cleavage

 

Authors: Tom Clough, Alexa Kennedy, Ellen Watts, Iva Zlatareva, Folake
Orafidiya, Hanna Buist, Jannah Jeon, Sophie Brown, Doug Sammon, Victoria
Juskaite, David Jones, Dave Liebowitz, Michelle Morrow, Francis Wilson

 

Speaker: Francis Wilson

 

Session: Poster Session C

 

Date and Time: Saturday, October 25, 12:30-4pm

 

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer                via ICR Healthcare

 Peel Hunt (Nomad and Joint Broker)                         www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare (Europe/UK media and investors)             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              carly@thrustsc.com (mailto:carly@thrustsc.com)

 Carly Scaduto

 THRUST Strategic Communications

 

About Avacta - www.avacta.com (https://avacta.com/)

 

Avacta is a clinical stage life sciences company developing an innovative
proprietary drug delivery peptide drug conjugate (PDC) platform,
pre|CISION(®). The pre|CISION(®) platform uniquely enables the repurposing
of a range of oncology drugs as PDC payloads with the goal to significantly
reduce toxicity and side effects for patients by concentrating the drug
directly in the tumor.

 

About pre|CISION(®)

 

The key aspect of pre|CISION(®) is its peptide drug conjugates (PDC)
technology.  The combination of the cancer drug and the proprietary cleavable
peptide (the PDC) is inert and incapable of entering cells and killing them
until the peptide is specifically released within the tumor. The active
payload in the pre|CISION(®) PDC is released when the PDC comes into contact
with the common tumor-associated protein, known as fibroblast activation
protein (FAP), in the tumor. The release of the payload from the
pre|CISION(®) product directly in the tumor results in higher concentration
of the drug at the tumor and lower blood and healthy tissue levels than
standard systemic administration, offering the potential to improve efficacy
and patient tolerability.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGUBDGXXBDGUX



            Copyright 2019 Regulatory News Service, all rights reserved